Delhi High Court Refuses to Restrain Dr Reddy’s from Manufacturing, Exporting Ozempic-Like Drug

The Delhi High Court refused to grant an interim injunction sought by Novo Nordisk, allowing Dr Reddy’s Laboratories to manufacture and export its version of the GLP-1 drug containing semaglutide.

The Court observed that Dr Reddy’s raised a credible challenge to Novo Nordisk’s patent claims, noting that the company had obtained two patents for minor variants of the same compound, amounting to “evergreening.”

The Court held that the species-specific patent was already claimed under a broader genus patent, and Novo Nordisk’s actions artificially extended its monopoly.

Dr Reddy’s is permitted to continue manufacturing the drug for export while the validity of the patent is examined.

[Novo Nordisk v. Dr Reddy’s Laboratories]